NanoVibronix, Inc. Files Amendment No. 1 to Annual Report on Form 10-K

TL;DR

<b>NanoVibronix, Inc. has filed an amendment to its 2023 annual report, confirming its reporting compliance and stock exchange listing.</b>

AI Summary

NanoVibronix, Inc. (FEED) filed a Amended Annual Report (10-K/A) with the SEC on April 9, 2024. NanoVibronix, Inc. filed an amendment (No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company's common stock, par value $0.001 per share, is registered under the trading symbol NAOV on the NASDAQ Capital Market. The filing indicates that NanoVibronix, Inc. is not a well-known seasoned issuer. The company has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days. NanoVibronix, Inc. has submitted electronically every Interactive Data File required for the preceding 12 months.

Why It Matters

For investors and stakeholders tracking NanoVibronix, Inc., this filing contains several important signals. This amendment provides updated or corrected information for the fiscal year 2023, which is crucial for investors to have the most accurate financial and operational data. The confirmation of compliance with SEC filing requirements and the listing on NASDAQ Capital Market are important indicators of the company's status and accessibility to public investors.

Risk Assessment

Risk Level: low — NanoVibronix, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, suggesting potential corrections or additions to previously reported information, but it does not indicate new material adverse events.

Analyst Insight

Investors should review the specific changes made in Amendment No. 1 to the 10-K filing to understand any updated disclosures regarding NanoVibronix, Inc.'s financial performance or operations for the fiscal year 2023.

Key Numbers

• 001-36445 — Commission File Number (NanoVibronix, Inc.)
• 2023-12-31 — Fiscal Year End (NanoVibronix, Inc.)
• 0001 — SEC File Number (NanoVibronix, Inc.)

Key Players & Entities

• NanoVibronix, Inc. (company) — Registrant name
• NASDAQ Capital Market (company) — Exchange where common stock is registered
• NAOV (company) — Trading symbol for common stock
• 2023-12-31 (date) — Fiscal year end date
• 2024-04-09 (date) — Filing date

FAQ

Industry Context

NanoVibronix, Inc. operates in the orthopedic, prosthetic & surgical appliances & supplies industry, focusing on medical devices.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.

What Investors Should Do

1. Review Amendment No. 1 to the 10-K for specific changes and updated disclosures.
2. Monitor future SEC filings from NanoVibronix, Inc. for ongoing financial and operational updates.
3. Verify the company's compliance status and stock listing details on the NASDAQ Capital Market.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-04-09: Filing Date — Date the amendment to the 10-K was filed with the SEC.

Year-Over-Year Comparison

This filing is an amendment (No. 1) to the previously filed 10-K for the fiscal year ended December 31, 2023, indicating updates or corrections to the original report.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share NAOV NASDAQ Capital Mark

Filing Documents

• form10-ka.htm (10-K/A) — 63KB
• form10-ka_001.jpg (GRAPHIC) — 13KB
• ex23-2.htm (EX-23.2) — 4KB
• ex31-1.htm (EX-31.1) — 7KB
• ex31-2.htm (EX-31.2) — 7KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-24-014096.txt (&nbsp;) — 357KB
• naov-20231231.xsd (EX-101.SCH) — 3KB
• naov-20231231_lab.xml (EX-101.LAB) — 36KB
• naov-20231231_pre.xml (EX-101.PRE) — 24KB
• form10-ka_htm.xml (XML) — 7KB

Financial Statements

Financial Statements No

financial statements are filed with this Amendment No. 1. These items were included as part of the Original Form 10-K

financial statements are filed with this Amendment No. 1. These items were included as part of the Original Form 10-K. (2)

Financial Statements Schedule

Financial Statements Schedule None. (3) Exhibits Index to Exhibits Exhibit No. Description 23.2* Consent of Marcum LLP, Independent Registered Public Accounting Firm 31.1* Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 31.2* Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 32.1** Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101* The following materials from the Company's Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Changes in Stockholders' Deficiency, (iv) Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** Furnished herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 9, 2024 NANOVIBRONIX, Inc. By: /s/ Stephen Brown Name: Stephen Brown Title: Chief Financial Officer

View Full Filing

View this 10-K/A filing on SEC EDGAR